AI Article Synopsis
- This study evaluates the quality of life (QOL) for patients with hepatocellular carcinoma (HCC) undergoing different treatments: transarterial radioembolization (TARE), the combination of atezolizumab and bevacizumab, and sorafenib.
- The methods involved analyzing patient data from the SARAH and IMbrave150 trials, adjusting for various health factors to ensure fair comparisons of QOL deterioration over time.
- Results showed that patients receiving TARE had a longer median time to deterioration in QOL compared to those on atezolizumab-bevacizumab, while those on sorafenib had the shortest median TTD in QOL.
Article Abstract
Introduction: Given the relatively short life expectancy of patients with hepatocellular carcinoma (HCC), quality of life (QOL) plays a significant role in treatment selection. This analysis aimed to compare time to deterioration (TTD) in QOL with transarterial radioembolization (TARE) and atezolizumab-bevacizumab, as well as sorafenib, in advanced and unresectable HCC.
Methods: Patient-level data from SARAH (TARE using SIR-Spheres Y-90 resin microspheres [SIR-Spheres] versus sorafenib) and aggregate data from IMbrave150 (atezolizumab-bevacizumab versus sorafenib) randomized controlled trials were used to conduct an anchored matching-adjusted indirect comparison (MAIC). Patients with a Child-Pugh score B in SARAH were excluded to align with exclusion criteria in IMbrave150. To identify potential effect modifiers for adjustment, the literature was searched and multivariate Cox proportional hazards models were implemented using SARAH data. Patients from SARAH were then weighted to balance with baseline characteristics from IMbrave150. Median TTD in QOL and hazard ratios (HRs) were calculated.
Results: Four potential effect modifiers were identified and used for adjustment: cause of disease (viral/non-viral), macrovascular invasion, Eastern Cooperative Oncology Group performance score, and alpha-fetoprotein level. The MAIC included 217 patients from SARAH (TARE = 94; sorafenib = 123). Median TTD in QOL was 11.23 and 8.64 months for atezolizumab-bevacizumab and TARE, respectively (HR = 1.06; 95% confidence interval [CI] 0.75-1.50; p = 0.725). A sensitivity analysis was conducted adjusting for cause of disease defined as hepatitis B/hepatitis C/non-viral: median TTD in QOL was higher for TARE compared with atezolizumab-bevacizumab (19.88 vs 11.23 months; HR = 0.66; 95% CI 0.36-1.19; p = 0.163). Sorafenib resulted in the shortest TTD in QOL, with statistically significant differences in both base case and sensitivity analyses.
Conclusion: TARE using SIR-Spheres may achieve similar TTD in QOL compared with atezolizumab-bevacizumab, as the analyses found no statistically significant differences between these two interventions. Both TARE using SIR-Spheres and atezolizumab-bevacizumab seem to be more efficacious than sorafenib in maintaining QOL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056454 | PMC |
| http://dx.doi.org/10.1007/s12325-022-02099-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.
Oncologist
September 2024
Department of Gastroenterology, University Hospital Pontchaillou, Rennes 1 University, INSERM U1242 "Chemistry Oncogenesis Stress Signalling," Rennes, France.
Article Synopsis
- The study investigates predictive markers for the benefits of LV5FU2 maintenance therapy after first-line FOLFIRINOX treatment in patients with metastatic pancreatic cancer.
- It compares two patient groups from the PRODIGE-35 trial: one receiving 12 cycles of FOLFIRINOX, and another receiving 8 cycles followed by LV5FU2 maintenance.
- Results indicate that certain factors, like age and metastatic sites, affect patient outcomes, suggesting that LV5FU2 maintenance is generally beneficial except for some specific cases.
Article Synopsis
- KEYNOTE-394 trial found that pembrolizumab significantly improved survival rates and quality of life for Asian patients with advanced liver cancer compared to a placebo.
- Health-related quality of life was assessed using two questionnaires, revealing that patients on pembrolizumab experienced less decline in their quality of life scores versus those on placebo at 12 weeks.
- The study concludes that pembrolizumab offers a meaningful benefit with acceptable safety for patients in need of second-line treatment for advanced hepatocellular carcinoma.
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.
Oncologist
October 2024
Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
Article Synopsis
- The KEYNOTE-590 study found that combining pembrolizumab with chemotherapy significantly improved survival rates and overall health outcomes for patients with advanced esophageal cancer compared to chemotherapy alone.
- A health-related quality of life analysis involving 730 patients showed that those receiving pembrolizumab plus chemotherapy experienced less dysphagia and pain compared to those on placebo plus chemotherapy, although overall quality of life scores were similar.
- The study concluded that pembrolizumab plus chemotherapy not only maintained quality of life after 18 weeks but also demonstrated effectiveness, supporting its use as a first-line treatment for advanced esophageal cancer.
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
J Clin Oncol
August 2024
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Purpose: In the phase III HIMALAYA study (ClinicalTrials.gov identifier: NCT03298451) in unresectable hepatocellular carcinoma (uHCC), the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen significantly improved overall survival versus sorafenib, and durvalumab monotherapy was noninferior to sorafenib. Patient-reported outcomes (PROs), a secondary outcome from HIMALAYA, are reported here.
View Article and Find Full Text PDFPatient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).
Int J Cancer
June 2024
Department of Thoracic Oncology, Thoraxklinik, University Hospital Heidelberg and Translational, Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Patients with lung cancer under treatment have been associated with a high risk of COVID-19 infection and potentially worse outcome, but real-world data on patient-reported outcomes (PROs) are rare. We assess patients' characteristics and PROs before and during the COVID-19 pandemic in an advanced non-small cell lung cancer (NSCLC) cohort in Germany. Patients with locally advanced or metastatic NSCLC from the prospective, multicentre, observational CRISP Registry (NCT02622581) were categorised as pre-pandemic (March 2019 to Feb 2020, n = 1621) and pandemic (March 2020 to Feb 2021, n = 1317).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!